Programmed death 1 (PD-1) is a T cell co-inhibitory receptor with two ligands, PD-L1 and PD-L2.
In cancer, this pathway plays a major role in immune resistance in the tumor environment. Blockade of this pathway can enhance antitumor immune responses. This review discusses the preclinical rationale for PD-1 pathway inhibition in advanced renal cell carcinoma and prostate cancer, in addition to the clinical activity and toxicity of the anti-PD-L1 antibody BMS-936559, as well as anti-PD-1 antibodies MK-3475 and BMS-936558.
Written by:
Tang PA, Heng DY. Are you the author?
Tom Baker Cancer Center, University of Calgary, 1331-29th St NW, Calgary, AB, T2N 4N2, Canada.
Reference: Curr Oncol Rep. 2012 Dec 22
PubMed Abstract
PMID: 23263823
